| Name | Title | Contact Details |
|---|
OncoCellMDx is a privately held company dedicated to the development and commercialization of novel diagnostic tests utilizing proprietary technologies created at Harvard Medical School. In particular, we have developed a noninvasive blood-based immunogenomic assays that will aid the physician to better understand the underlying pathology. The first product is for assessing the severity of prostate cancer. Other oncology indications as well as non-oncology indications are part of our pipeline. The assay is based on examining specific transcription levels between phagocytic and non-phagocytic cells. This proprietary technology and algorithm has allowed us to not only detect disease but to also, and more importantly, guide the physician as to the grade and aggressiveness of the disease. Our mission is to provide clinicians with quantifiable results that allows professionals to make timely and much more directed medical decisions.
FibroGen is a research-based biotechnology company using its expertise in connective tissue growth factor (CTGF) and hypoxia-inducible factor (HIF) biology to discover, develop, and commercialize novel therapeutics for serious unmet medical needs. FibroGen’s research team is committed to discovering novel therapies in areas of major unmet medical need. Our goal is to continue to provide pipeline candidates supported by rigorous data in well-characterized therapeutic settings. All of FibroGen`s therapeutic candidates have been internally developed based on FibroGen`s pioneering research in two important areas of biology, hypoxia-inducible factor (HIF) and connective tissue growth factor (CTGF).
Osseon Therapeutics is a Santa Rosa, CA-based company in the Healthcare, Pharmaceuticals, and Biotech sector.
Contec Vision is a Waltham, MA-based company in the Healthcare, Pharmaceuticals, and Biotech sector.
Harbor Health Elder Service Plan is a Dorchester Center, MA-based company in the Healthcare, Pharmaceuticals, and Biotech sector.